Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B McCall

Showing results (221-230 of 242) with videos related to

Pageof 25
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1996
Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonistK M Merchant, G S Gill, D W Harris, et al.
The Lancet. Infectious Diseases|December 19, 2025
Efficacy of ProC6C-AlOH/Matrix-M against Plasmodium falciparum infection and mosquito transmission: a phase 2, randomised, controlled human malaria infection studyMamady Kone, Jordan Plieskatt, Moussa Thienta, et al.
The Lancet. Infectious Diseases|September 19, 2025
Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trialSelidji T Agnandji, Jeroen Bok, Ayodele Alabi, et al.
The Journal of Infection|February 19, 2026
Controlled human pneumococcal infection in the Netherlands: colonisation, antibody responses and the impact of viral co-infectionLucille F van Beek, Suzanne E T Comans, Koen Totté, et al.
BMC Medicine|April 22, 2024
A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trialM Alkema, M J Smit, C Marin-Mogollon, et al.
Plos Neglected Tropical Diseases|August 28, 2023
Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trialRella Zoleko-Manego, Ruth Kreuzmair, Luzia Veletzky, et al.
The Journal of Infectious Diseases|November 26, 2009
Early interferon-gamma response against Plasmodium falciparum correlates with interethnic differences in susceptibility to parasitemia between sympatric Fulani and Dogon in MaliMatthew B B McCall, Joost Hopman, Modibo Daou, et al.
European Cytokine Network|April 29, 2010
Persistence of full-length caspase-12 and its relation to malaria in West and Central African populationsMatthew B B McCall, Bart Ferwerda, Joost Hopman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2018
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <i>RAS</i> Wild-Type Metastatic Colorectal CancerAndrew G Hill, Michael P Findlay, Matthew E Burge, et al.
The Lancet. Microbe|May 11, 2022
Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trialWill Stone, Almahamoudou Mahamar, Merel J Smit, et al.
Pageof 25

Showing results (221-230 of 242) with videos related to

Sort By:
Pageof 25
The Journal of Pharmacology and Experimental Therapeutics|December 1, 1996
Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonistK M Merchant, G S Gill, D W Harris, et al.
The Lancet. Infectious Diseases|December 19, 2025
Efficacy of ProC6C-AlOH/Matrix-M against Plasmodium falciparum infection and mosquito transmission: a phase 2, randomised, controlled human malaria infection studyMamady Kone, Jordan Plieskatt, Moussa Thienta, et al.
The Lancet. Infectious Diseases|September 19, 2025
Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trialSelidji T Agnandji, Jeroen Bok, Ayodele Alabi, et al.
The Journal of Infection|February 19, 2026
Controlled human pneumococcal infection in the Netherlands: colonisation, antibody responses and the impact of viral co-infectionLucille F van Beek, Suzanne E T Comans, Koen Totté, et al.
BMC Medicine|April 22, 2024
A Pfs48/45-based vaccine to block Plasmodium falciparum transmission: phase 1, open-label, clinical trialM Alkema, M J Smit, C Marin-Mogollon, et al.
Plos Neglected Tropical Diseases|August 28, 2023
Efficacy, safety, and tolerability of albendazole and ivermectin based regimens for the treatment of microfilaraemic loiasis in adult patients in Gabon: A randomized controlled assessor blinded clinical trialRella Zoleko-Manego, Ruth Kreuzmair, Luzia Veletzky, et al.
The Journal of Infectious Diseases|November 26, 2009
Early interferon-gamma response against Plasmodium falciparum correlates with interethnic differences in susceptibility to parasitemia between sympatric Fulani and Dogon in MaliMatthew B B McCall, Joost Hopman, Modibo Daou, et al.
European Cytokine Network|April 29, 2010
Persistence of full-length caspase-12 and its relation to malaria in West and Central African populationsMatthew B B McCall, Bart Ferwerda, Joost Hopman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2018
Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line <i>RAS</i> Wild-Type Metastatic Colorectal CancerAndrew G Hill, Michael P Findlay, Matthew E Burge, et al.
The Lancet. Microbe|May 11, 2022
Single low-dose tafenoquine combined with dihydroartemisinin-piperaquine to reduce Plasmodium falciparum transmission in Ouelessebougou, Mali: a phase 2, single-blind, randomised clinical trialWill Stone, Almahamoudou Mahamar, Merel J Smit, et al.
Pageof 25